Arcellx Inc.

68.08
-0.43 (-0.63%)
At close: Mar 28, 2025, 3:59 PM
66.07
-2.95%
After-hours: Mar 28, 2025, 06:28 PM EDT
-0.63%
Bid 61.3
Market Cap 3.74B
Revenue (ttm) 110.45M
Net Income (ttm) -109.85M
EPS (ttm) -2
PE Ratio (ttm) -34.04
Forward PE -28.72
Analyst Buy
Ask 75
Volume 283,894
Avg. Volume (20D) 641,511
Open 68.54
Previous Close 68.51
Day's Range 66.69 - 68.92
52-Week Range 47.88 - 107.37
Beta 0.32

About ACLX

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent Sp...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 4, 2022
Employees 163
Stock Exchange NASDAQ
Ticker Symbol ACLX
Full Company Profile

Analyst Forecast

According to 12 analyst ratings, the average rating for ACLX stock is "Buy." The 12-month stock price forecast is $114, which is an increase of 67.45% from the latest price.

Stock Forecasts

Next Earnings Release

Arcellx Inc. is scheduled to release its earnings on May 8, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
+0.79%
Acrellx shares are trading lower after the company... Unlock content with Pro Subscription
7 months ago
+12.31%
Arcellx shares are trading higher after the company reported better-than-expected Q2 financial results.